证券代码：301408 证券简称：华人健康 公告编号：2025-044 安徽华人健康医药股份有限公司 关于收购福建、浙江三家医药连锁公司股权的进 展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 安徽华人健康医药股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开第五届董事会第九次会议，以 9 票同意、0 票反对、0 票弃权的表决结果审 议通过了《关于收购福建、浙江三家医药连锁公司股权的议案》，同意公司以人 民币 13,342.90 万元的价格购买宁波闽哲汇投资合伙企业（有限合伙）（以下简 称"闽哲汇"）持有的福建省扬祖惠民医药连锁有限公司（以下简称"扬祖惠民"） 46.01%股权、以人民币 12,514.72 万元的价格购买闽哲汇持有的福建海华医药连 锁有限公司（以下简称"海华医药"）46.01%股权以及以人民币 6,825.975 万元 的价格购买闽哲汇持有的桐庐怡生堂大药房连锁有限公司（以下简称"桐庐怡生 堂"）70.01%股权。 公司于 2025 年 5 月 19 日与闽哲汇就前述三个目标公司的股权收购事宜分 别 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-043 统一社会信用代码：91340100730002825G 安徽华人健康医药股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开第五届董事会第九次会议、2025 年 6 月 6 日召开 2025 年第一次临时股东大 会，分别审议通过了《关于增加经营范围及修订<公司章程>的议案》，具体情况 详见公司披露于巨潮资讯网（www.cninfo.com.cn）的《关于增加经营范围及修 订<公司章程>的公告》（公告编号：2025-038）、《2025 年第一次临时股东大会 决议公告》（公告编号：2025-042）。近日，公司已完成上述工商变更登记及《公 司章程》的备案手续，并取得合肥市市场监督管理局换发的《营业执照》。具体 情况如下： | 变更事项 | 原登记内容 | 变更后登记内容 | | --- | --- | --- | | | 许可项目：药品批发；药品委托生产 ...

A股医药商业板块水下拉起，一心堂封板涨停，漱玉平民、健之佳、华人健康、第一医药、益丰药房等 跟涨。 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-042 安徽华人健康医药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 6 月 6 日（星期五）下午 14：00。 （2）网络投票时间：通过深圳证券交易所互联网系统投票的时间为 2025 年 6 月 6 日 9:15-15:00；通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 6 月 6 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 2、现场会议召开地点：安徽省合肥市包河区上海路 18 号华人健康大厦 6 楼 601 会议室。 3、会议召开方式：本次会议采取现场投票和网络投票相结合的方式召开。 4、会议召集人：董事会。 5、会议主持人：董事长何家乐。 6、本次会议的召集、召开符合《中华人民共和 ...

之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年六月 国浩律师（上海）事务所 国浩律师（上海）事务所 关 于 安徽华人健康医药股份有限公司 2025 年第一次临时股东大会 关于安徽华人健康医药股份有限公司 2025 年第一次临时股东大会之法律意见书 致：安徽华人健康医药股份有限公司 安徽华人健康医药股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会于 2025 年 6 月 6 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师参加了公司本次股东大会的全过程，并根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）等法律 ...

华夏时报（www.chinatimes.net.cn）记者 于娜 见习记者 赵文娟 北京报道 在医药零售行业整体放缓扩张节奏的背景下，安徽头部连锁药房企业华人健康（301408.SZ）却反其道而行之，再 次抛出重磅收购计划。近日，公司公告拟以3.27亿元现金收购福建、浙江三家医药连锁公司股权，其中一家标的 资产评估增值率高达近24倍，引发市场对其激进扩张模式的深度审视。 据《华夏时报》记者不完全统计，这已是其2023年上市以来的第6次较大的股权收购，截至2025年一季度末，公司 商誉随之飙升至9.88亿元。耐人寻味的是，在管理层大举并购的同时，阿里健康、华泰大健康、赛富投资等机构 股东却在密集减持。这场"激进扩张"与"资本撤退"的角力，折射出医药零售行业整合期的深层矛盾。《华夏时 报》记者致函华人健康，采访公司并购及股东减持等问题，截至发稿未收到回复。 华人健康"三高"并购隐忧凸显 与行业整体放缓扩张步伐不同，华人健康自上市以来一直不停地买买买。 华人健康是一家医药流通企业，目前覆盖医药零售、医药代理及终端集采、研发生产等领域。由于起步于安徽省 合肥市，长期聚焦省内市场，华人健康稳居安徽地区龙头连锁药店地位。 ...

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. plans to acquire equity stakes in three pharmacy chains for a total of 327 million yuan, aiming to enhance its market share and brand influence in East China [1][2] Group 1: Acquisition Details - The company intends to purchase 46.01% of Fujian Yangzuo Huimin Pharmaceutical Chain Co., Ltd. for 133.4 million yuan, 46.01% of Fujian Haihua Pharmaceutical Chain Co., Ltd. for 125.1 million yuan, and 70.01% of Tonglu Yishengtang Pharmacy Chain Co., Ltd. for 68.3 million yuan [2] - The funding for the acquisitions will come from the company's own funds and a change in the use of part of the raised funds, with 130 million yuan allocated for the acquisitions if approved [2] Group 2: Financial Performance and Valuation - The estimated revenue and net profit for the acquired companies in 2024 are as follows: Yangzuo Huimin 294 million yuan revenue and 5.615 million yuan net profit, Haihua Pharmaceutical 270 million yuan revenue and 11.056 million yuan net profit, and Yishengtang 96.46 million yuan revenue and 0.264 million yuan net profit [3] - The valuation increase rates for the acquired companies are significant: Yangzuo Huimin at 892.79%, Haihua Pharmaceutical at 1029.4%, and Yishengtang at 2350.84% [3] Group 3: Growth and Expansion - Since its listing in March 2023, the company has conducted 22 asset purchase transactions totaling over 1 billion yuan, with major investments including 876 million yuan for five significant equity investments [4] - The company has expanded its store count significantly, adding 440 stores in 2024, with a total of 1,774 stores by the end of the year [6] Group 4: Shareholder Activity - Despite the company's growth, it has faced significant shareholder sell-offs, with major shareholders reducing their stakes, including Alibaba Health and Huatai Health [7][8] - The company has stated that these sell-offs are based on the shareholders' operational and financial needs, and management remains confident in the company's future [8]

Core Viewpoint - The Chinese pharmaceutical retail market is experiencing robust growth due to increasing health awareness and rising healthcare demands, with a projected annual growth rate of 5% to 6% by 2025 [1] Company Summary - Anhui Huaren Health Pharmaceutical Co., Ltd. plans to acquire equity stakes in three pharmaceutical chain companies in Fujian and Zhejiang provinces for approximately 327 million yuan [1] - The acquisitions include a 46.01% stake in Yangzu Huimin Pharmaceutical Chain Co., Ltd. for 133 million yuan, a 46.01% stake in Fujian Haihua Pharmaceutical Chain Co., Ltd. for 125 million yuan, and a 70.01% stake in Tonglu Yishengtang Pharmacy Chain Co., Ltd. for 68.26 million yuan [1] - The company aims to deepen its market presence in East China and leverage the acquired companies' networks, brand recognition, and customer resources to enhance its market share and brand influence locally [1] Industry Summary - The performance commitment agreements signed with the acquired companies set sales targets of no less than 295 million yuan, 310 million yuan, and 325 million yuan for the years 2025, 2026, and 2027, respectively, along with corresponding net profit targets [2] - The acquisition is expected to impact the competitive landscape of the pharmaceutical retail market in East China, prompting other companies to accelerate their own expansion and consolidation efforts [2] - The move serves as a reference case for industry consolidation, promoting a trend towards scale and concentration within the sector [2] - The company plans to continue its strategy of focusing on East China while optimizing its industry layout and enhancing service quality and customer experience [2] - With the advancement of internet technology and changing consumer purchasing habits, the company will explore an online-offline integration model to improve operational efficiency and market competitiveness [3]

Group 1 - Qingmu Technology plans to reduce its shareholding by up to 3%, amounting to no more than 2.776 million shares [1] - Newcap received a decision from the police to revoke the case against its actual controller, who was previously detained for insider trading [2] - Rhine Biotech's directors and executives plan to collectively reduce their holdings by up to 0.14%, totaling no more than 1.0185 million shares [3] Group 2 - Puli Tui's stock and convertible bonds will be delisted on May 22, 2025 [5] - *ST Nong Shang will have its delisting risk warning lifted and will resume trading on May 23, 2025 [7] - State Grid Information Communication plans to acquire 100% equity of Yili Technology for approximately 1.853 billion yuan [9] Group 3 - Kelun Pharmaceutical's subsidiary received drug registration approval for a new injectable product, which is the first of its kind in China [10] - Aishida plans to acquire 7% equity of its subsidiary Zhejiang Qianjiang Robot Co., Ltd. for 13.09 million yuan [11] - Hongming Co. is planning to acquire 83% equity of Shenzhen Chisu Automation Equipment Co., Ltd. for approximately 151 million yuan [12] Group 4 - JuJiao Co. plans to reduce its shareholding by up to 2.6%, totaling no more than 2.093 million shares [14] - AVIC Financial's stock will be delisted on May 27, 2025 [16] - Jingwang Electronics' major shareholders plan to reduce their holdings by up to 2.99% [17] Group 5 - Huaren Health intends to acquire stakes in three pharmaceutical chain companies for a total of 327 million yuan [18] - Huanrui Century's original shareholders are required to compensate for unfulfilled performance commitments with 116 million shares [20] - Tefa Service's shareholders plan to reduce their holdings by up to 3% [21] Group 6 - Maipu Medical is planning to acquire at least 51% of Easy Medical's equity, which will constitute a major asset restructuring [22] - *ST Jinshi will have its delisting risk warning lifted and its stock will resume trading on May 23, 2025 [22] - Guoke Micro is planning a major asset restructuring and will suspend trading [23] Group 7 - Defu Technology intends to acquire 100% equity of an overseas electronic circuit copper foil company [24] - Xince Standard's shareholder plans to reduce its holdings by up to 1% [25] - Xiouqiang Co. plans to reduce its holdings by up to 3% [27]

Core Viewpoint - The competition among major platforms like Ele.me, JD.com, and Meituan in the food delivery sector has expanded into the pharmaceutical category, leading to a significant rise in the instant retail of medicines, with platforms investing in traffic resources, supply chains, and innovative marketing strategies [1][4]. Group 1: Market Dynamics - The instant retail of pharmaceuticals is experiencing rapid growth, becoming a crucial part of the outpatient pharmaceutical retail market [1][4]. - JD Health's "Buy Medicine in Seconds" feature has seen a threefold increase in order volume due to enhanced traffic resources [4][6]. - The instant retail sector is evolving from high-frequency to low-frequency demand, now covering a full range of categories, including pharmaceuticals [5][6]. Group 2: Platform Strategies - JD.com has prominently featured "24h Delivery of Medicines" on its app, enhancing visibility and traffic for its instant retail services [3][4]. - Meituan has launched its instant retail brand "Meituan Flash Purchase," further intensifying competition in the pharmaceutical retail space [4][6]. - Taobao's instant retail service has been upgraded to "Taobao Flash Purchase," which includes a significant category for purchasing medicines [3][4]. Group 3: Industry Trends - The transformation of physical pharmacies is driving the adoption of instant retail, as many pharmacies are closing, leading to a competitive environment where digital solutions are essential [7][8]. - The integration of online medical services with instant retail is creating a comprehensive service model for users, enhancing the purchasing experience [7][8]. - The collaboration among platforms, pharmaceutical companies, and pharmacies is deepening, allowing for more effective marketing and sales strategies [8][10]. Group 4: Financial Performance - One Heart Hall's new retail segment saw a 47.6% year-on-year increase in revenue, with the O2O instant retail channel contributing 78.2% [15][16]. - Yifeng Pharmacy reported online sales of 2.127 billion yuan in 2024, with 1.721 billion yuan coming from O2O, accounting for 80.9% of total online sales [16][17]. - The overall trend indicates that if online medical insurance is fully opened, the share of instant retail in physical pharmacies could rise to 32.1% by 2030 [16][17]. Group 5: Future Outlook - The competition for instant retail in pharmaceuticals among major platforms is expected to continue, with Douyin's unique position in social media marketing presenting both opportunities and challenges [18]. - The penetration of instant retail in lower-tier markets is anticipated to grow, making it a significant growth driver in the outpatient pharmaceutical retail market [18].